GlobeNewswire·Aug 19, 2026, 8:00 AM ET

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

MNPR

Monopar Therapeutics Inc. appointed Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs, effective September 1, 2026.
Dr. Kent will lead the medical affairs organization as the company prepares for potential FDA approval of the New Drug Application for ALXN1840.
Dr. Kent brings over 20 years of biopharmaceutical experience, including leadership roles at Sling Therapeutics, Horizon Therapeutics, Abbott Laboratories, and Searle/Pharmacia.
Two abstracts regarding the late-stage candidate ALXN1840 (tiomolibdate choline) for Wilson disease were accepted for presentation at AASLD The Liver Meeting 2026 in Denver, Colorado.
An oral presentation titled "Residual hepatic, neurologic, and psychiatric disease burden in treatment-experienced patients with Wilson disease" will be delivered on November 8, 2026, by Frederick K. Askari, M.D., Ph.D.
A poster presentation titled "Neutral molybdenum balance and lack of molybdenum toxicity in subjects treated with tiomolibdate choline" will be presented on November 5, 2026, by Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D.
The abstracts are scheduled for public release by AASLD on October 5, 2026, with materials to be published in the October supplement of Hepatology.
ALXN1840 is a first-in-class albumin tripartite complex activator that demonstrated rapid copper mobilization in a Phase 3 trial, meeting its primary endpoint over 48 weeks.
The Phase 3 trial observed durable clinical improvement and a favorable safety profile across 645 patient-years of follow-up involving 266 patients.
Monopar Therapeutics also maintains radiopharmaceutical programs for advanced cancers, including MNPR-101-Zr (Phase 1), MNPR-101-Lu (Phase 1a), and MNPR-101-Ac (late preclinical).